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We used a series of deletion mutations in the 59 untranslated region of the prototype D type retrovirus, Mason-Pfizer
Monkey Virus (MPMV), to analyse RNA encapsidation. A region was identified upstream of the major splice donor which
reduced particle production but had a proportionally greater effect on RNA packaging. A small deletion downstream of the
splice donor had little effect on RNA production and caused no significant packaging defect. A large deletion encompassing
the end of the primer binding site down to the splice donor had a dramatic effect, disrupting viral protein synthesis. Stable
cell lines were produced containing packaging-defective virus. These first-generation packaging cell lines were used to
emic Prepackage and transfer an MPMV-based vector. © 2001 Acad
INTRODUCTION
Retroviruses encapsidate two copies of their full-
length unspliced RNA into the viral particle. This RNA
species codes for the Gag proteins of the virus and, by a
variety of frame-shifting procedures, also codes for the
protease and polymerase enzymes. The mechanism of
RNA/protein recognition and selection of the genomic
RNA against a background of a vast excess of structur-
ally similar capped, polyadenylated cellular mRNA mol-
ecules is unclear. In a number of retroviruses, cis-acting
sequences have been identified in the 59 leader which
are important or essential for RNA encapsidation (Linial
and Miller, 1990). Deletion of these regions commonly
leads to a packaging-defective phenotype in which viral
particles with grossly reduced or absent genomic RNA
content are produced. Much work has been done study-
ing RNA encapsidation in murine C type retroviruses
and, more recently, in lentiviruses both to understand the
mechanism of the process and to generate retroviral
vectors based on these viruses (Lever et al., 1989; Kim et
l., 1994; Luban and Goff, 1994). D type viruses, of which
ason-Pfizer Monkey Virus is the prototype, have been
nalysed much less intensively. One study (Vile et al.,
992) using an MPMV-based2 vector and a wild-type
1 To whom correspondence should be addressed at Department of
edicine, Box 157, Addenbrooke’s Hospital, Hills Road, Cambridge,
B2 2QQ, UK. Fax: 144-1223-336846. E-mail: amll1@mole.bio.
am.ac.uk.
2 Abbreviations used: DMEM, Dulbecco’s modification of Eagle’s
medium; FCS, fetal calf serum; ICAP, intracytoplasmic assembled par-
ticle; LTR, long terminal repeats; OD, optical density; ORF, open reading
frame; PBS, primer binding site; RT, reverse transcriptase; TBS, Tris-
buffered saline; UTR, untranslated region.
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helper virus demonstrated that sequences conferring
packaging specificity were sited at the 59 end of the virus
but did not define the region precisely. A number of RNA
secondary structures have been mapped and modelled
in the leader sequence of some C type retroviruses and
stable structures identified which are conserved be-
tween closely related viruses and which have been
shown to be localised at sites containing encapsidation
signals (Harrison and Lever, 1992; Baudin et al., 1993;
Knight et al., 1994). In a previous study we modelled the
RNA secondary structure of the 59 leader of Mason-Pfizer
Monkey Virus and identified a stable GC-rich stem loop
motif which was highly conserved in a number of retro-
viruses both closely and quite distantly related to MPMV
(Harrison, Hunter, and Lever, 1995). The structural con-
servation suggested that this motif encompassed an
important cis-acting sequence and this was used to help
direct our studies on the packaging signals of MPMV.
D type viruses are potentially of great interest in study-
ing encapsidation in that they assemble their capsids
intracellularly before transporting them to the plasma
membrane for interaction with the viral envelope, and
hence intracellular viral capsids can be isolated (Rhee
and Hunter, 1987; Rhee, Hui, and Hunter, 1990). The point
at which the RNA/protein interaction occurs in retroviral
encapsidation is not known and the ability to isolate and
analyse such capsids would provide useful clues to this
process. As a first step towards this, the identification of
cis-acting packaging sequences and the production of
packaging-defective virus particles is necessary. We
therefore carried out a deletion analysis of the 59 leader
sequence of MPMV in order to identify encapsidation
signals. We went on to establish stable cell lines ex-
0042-6822/01 $35.00
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8 ON Epressing packaging-defective viruses as a first step to-
wards a retroviral vector system based on MPMV and
demonstrated gene transfer of an MPMV-based vector.
RESULTS
The deletion mutants studied are shown in Fig. 1.
Deletions MPSB and MPSC are sited on either side of
the splice donor, leaving this sequence intact. MPSA is a
much larger deletion encompassing the whole of the
region from the primer binding site (PBS) to the splice
donor, including the 39 terminus of the PBS.
esults of transient transfection of wild-type virus
nd MPS mutants into COS and 293-T cells
Table 1 demonstrates the level of RT activity obtained
hen the various mutants were transfected into com-
only used cell lines. MPSA leads to a profound defect
n particle production, with RT levels no different from
ackground. MPSB shows a defect in RT containing
article production varying in different cell transfections
rom less than 10 to 37% of the wild-type value. MPSC
hows relatively small decreases in particle production
n all cell lines, with COS and 293-T cells generating
alues ranging from 37 to 77% of wild-type levels of
irions. These results confirm that deletions upstream of
he major splice donor have more effect on virion pro-
uction than does a small deletion between the splice
onor and the beginning of the gag gene.
TABLE 1
Percentage of RT Activity from Cells Transiently Transfected with
SHRM15 and the Plasmids Bearing C Deletions (Mean of Four
Values)
Cell type pSHRM15 pMPSA pMPSB pMPSC Control
COS 7 100 (1431) 8 9.5 37 4.5
293 T 100 (10,228) 4 37 77 4.5
FIG. 1. Diagram of the 59 end of the MPMV genome indicating the site
and size of the deletions introduced in this study. LTR, long terminal
repeat; PBS, primer binding site; SD, splice donor. Convenient restric-
tion sites are indicated.
2 GUESDNote. Absolute RT activity is expressed in Units/ml for pSHRM15 in
arentheses.iral protein production in transient transfections
Figure 2A demonstrates immunoprecipitation of pro-
eins from COS cell transfections comparing MPSA and
with wild-type virus. The Pr78gag protein is arrowed (for
explanation of the other bands see Rhee and Hunter
(1990). Wild-type protein expression (pSHRMI5) is dem-
onstrated in lane 3, MPSA in lane 2, and MPSB in lane 1.
MPSB gives rise to reduced but easily detectable viral
protein production, whereas the MPSA mutation grossly
disrupts protein production. In lane 2 are seen a re-
stricted number of bands compared to lanes 1 and 3.
Specifically, the major Gag protein is missing. However,
there is some slight enhancement of Pr68 over and
above the level of a similar band in the control lane. This
is consistent with MPSA disrupting usage of the initiation
codon of Gag, leading to abnormal initiation at an inter-
FIG. 2. Viral protein synthesis, processing, and virus production in
transiently transfected COS 7 cells. (A) Viral protein processing with
pSHRM15 and the C deletion mutants. Identical volumes of precleared
cytosolic proteins and viral particles were immunoprecipitated with
goat anti-MPMV 72-752 antibody overnight at 4°C and half of each
immunoprecipitation reaction was electrophoresed on an 11% PAGE
gel. Lane 1, MPSB; lane 2, MPSA; lane 3, pSHRM15; and lane 4, control
cells. The arrow indicates the position of the Pr78gag. (B) Viral protein
synthesis and processing in transiently transfected COS 7 cells: pulse–
chase. Precleared cytosolic proteins from a 15-min pulse experiment
(lanes 1, 4, 7, and 10), pulse followed by a 4-h chase in unlabelled
medium (lanes 2, 5, 8, and 11) and viral particles pelleted after a 4-h
chase (lanes 3, 6, 9, and 12) were immunoprecipitated with goat
anti-MPMV 72-752 antibody. Half of each immunoprecipitation reaction
was electrophoresed on an 11% PAGE gel. Lanes 1–3 are samples from
the control plate; lanes 4–6 from cells transiently transfected with 10 mg
of pSHRM15; lanes 7–9 from cells transfected with 10 mg of plasmid
PSB; and lanes 10–12 from cells transfected with 10 mg of plasmid
MPSC. The M r markers are identical to those in A and indicated with
ars.
T AL.nal methionine in the Matrix protein. This phenomenon
has been seen before and it is known that Pr68 is
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IRUS 5insufficient for viral particle release (M. Sakhalian, un-
published observations).
Figure 2B compares mutants MPSB and MPSC to the
wild type in a pulse–chase format. The cell-associated
proteins in pulse and chase for wild-type virus can be
seen clearly in lanes 4 and 5 compared to the control
(untransfected) lanes 1 and 2, and virions are detectable
in the supernatant (lane 6). Comparison of lanes 4 to 6
with lanes 7 to 9 (MPSB) and lanes 10 to 12 (MPSC)
shows a minor reduction in viral protein production for
MPSC but a good level of virion export. MPSB affects
viral protein production more profoundly but virions are
still detectable in the supernatant.
RNA encapsidation in virions produced from
transfected COS cells
Figure 3 shows a representative RNase protection
assay from a transient COS cell transfection. The size
markers are indicated to the left of the gel. The bands at
FIG. 3. RNase protection analysis of the packaging mutants. Lane 1,
NA size markers (Ambion); lanes 2–5, cytoplasmic RNA: lane 2,
SHRM15; lane 3, MPSA; lane 4, MPSB; lane 5, MPSC; lanes 6–9, virion
NA: lane 6, pSHRM15; lane 7, MPSA; lane 8, MPSB; lane 9, MPSC.
rrows indicate the expected positions of unspliced (top) and spliced
bottom) RNA.
MASON-PFIZER MONKEY V553 (lanes 2 and 6) demonstrate intracellular and virion
full-length RNA, respectively, demonstrating efficient en-capsidation by wild-type virus. MPSA, expected to give a
dominant band at 309, is easily seen in the cytoplasm
(lane 3). However, no virion RNA can be detected in the
supernatant preparation (lane 7). This was a reproduc-
ible finding. In lane 4, MPSB-specific bands can be seen
at 315 and 170 in the cellular sample, consistent with the
presence of full-length RNA. By contrast, a significantly
reduced level of RNA is detected in the virion preparation
in lane 8. RNA from MPSC cells (lane 5) contain bands
consistent with full length genomic RNA at 249 and 286.
These are also detected in the virion lane (lane 9). The
results demonstrate that RNA packaging is inefficient in
MPSB. RNA encapsidation by MPSC is similar to that of
the wild type. The RNase protection analysis confirms
data obtained from slot-blot analyses of the relative effi-
ciencies of these viruses in encapsidating RNA (not
shown). Image analysis of these bands from replicate
gels in which the ratio of genomic to spliced viral mRNA
in cell and virion is compared shows a relative packag-
ing efficiency of MPSB of 58% and MPSC of 100% relative
to the wild type calculated as previously described (Ri-
chardson and Lever, 1995).
Establishment of first-generation MPMV packaging
cell lines
Stable cell lines containing wild-type MPMV, MPSB,
and MPSC were established, taking advantage of the
hygromycin resistance gene in the flanking DNA. Two
cell lines were used, SV2 and SW480, both of which grow
as monolayers. For MPSB and MPSC, colony cloning
was used to produce high RT expressing cells. Table 2
demonstrates the RT levels in two of these clonal cell
populations, MPSB7 and MPSC1, compared to a pool of
wild-type infected cells. The RT activity in both of these
mutants was stable until the 14th passage and then
declined in all cells. MPSC1 produces comparable or
superior RT activity to that of the wild-type cells, whereas
MPSB7 RT activity is consistently lower. In SW480 cells,
cell populations were generated expressing wild-type,
MPSB, and MPSC viruses. The MPSB clone expressed
RT relatively transiently but this declined to background
level. MPSC11A produced reasonably stable RT activity
through five passages at a level approximately 50% of
that of the wild type. These results confirm that MPMV
structural proteins can be expressed through a pro-
longed number of passages in certain cell types.
Protein production in stably expressing cells
Pulse–chase experiments confirm the expression of
virion proteins from stably transfected SW480 cells cor-
relating with the RT results (data not shown). Figure 4
demonstrates pulse–chase data from SV2 cells trans-
839 PACKAGING SEQUENCEfected with the wild-type virus (lanes 1 to 3). The CMMT
cell line, which is a known high particle producer stably
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ON Eexpressing MPMV, is shown in lanes 4 to 6, the control
untransfected cell line in lanes 7 to 9, and the clonal cell
lines from leader deletion mutants MPSB7 (lanes 10 to
12) and C1 (lanes 13 to 15) are shown on the righthand
side of the gel. In each triplet, the lefthand lane demon-
strates virion production, the central lane shows a 15-min
chase, and the righthand lane the 4-h chase. The results
show that the viral protein and export from the MPSB7
and MPSC1 clonal cell populations are approximately
equivalent to that from the pooled cells transfected with
wild-type virus.
TABLE 2
(A) RT Values of SV2 Cells Containing Wild-Type MPMV (Cell Line)
or C Deletion Mutants (Clones)
Passage
SV2
control
SV2 wt
pool SV2/MPSB7 SV2/MPSC1
2 119 294 152 238
3 190 335 262 186
4 219 n.d. 321 312
7 742 3393 2235 4378
11 516 13689 7160 19301
14 646 29415 4115 29059
18 n.d. 7990 3062 6724
(B) RT Values of SW480 Cells Containing Wild-Type MPMV
(Cell Line) or C Deletion Mutants (Clones)
SW480
control
SW480/wt
7A
SW480/wt
5A
SW480/
MPSB.3A
SW480/
MPSC.11A
3 140 5151 4271 1268 3099
4 196 8592 5274 547 2243
5 786 2501 4257 400 2380
FIG. 4. Pulse–chase labelling and immunoprecipitation of pSHRM15
nd C deletion mutants in SV2 cell lines and clones and the CMMT cell
line. Subconfluent 60-mm culture dishes were pulse–chase labelled
(see Materials and Methods), and precleared cytosolic and extracellu-
lar virus samples were immunoprecipitated with goat anti-MPMV 72-
752. Half of each reaction was loaded on an 11% PAGE gel and
electrophoresed. The M r standards are identical to those in Fig. 2. The
rrowhead indicates the position of the p27. Lanes 1, 4, 7, 10, and 13 are
xtracellular pelleted virions. Lanes 2, 5, 8, 11, and 14 are cytosolic
amples resulting from the 15-min pulse, and lanes 3, 6, 9, 12, and 15
re cytosolic samples from the 4-h chase. Lanes 1–3, SV2 wt pool cells;
84 GUESDanes 4–6, CMMT cell line; lanes 7–9, original SV2 cell line; lanes
0–12, SWV/MPSB7; lanes 13–15, SW2/MPSC1.RNA encapsidation in stable cell lines
Virions produced from these stable SV2 cells were
normalised by RT assay, pelleted, and RNA extracted.
The preparations were assessed for RNA encapsidation
by slot-blot analysis. Figure 5 demonstrates encapsida-
tion of RNA from the MPSC1 producing cell line and, as
expected, variable but consistently detectable encapsi-
dation from the wild-type virus expressors (lanes 3 and 5,
pooled cells; lane 4, wild-type clonal cell lines). MPSB7
clonal cell line shows very little RNA at all in virions
(lane 2).
Vector transfer was achievable from the prototype pro-
ducer cell lines into both HeLa B and SV2 target cells
using vectors p16.5 and p16.2 (Fig. 6). The titre was low
at around 101–102 CFU/ml, being optimal in the presence
f polybrene. The producer cell lines were also assayed
t weekly intervals for detection of a rise in reverse
ranscriptase, which would be indicative of generation of
ecombinant wild-type virus but no alteration in this level
as seen (data not shown).
DISCUSSION
The experiments described above throw light on cis-
cting functions in the untranslated region of MPMV. The
PSA deletion leads to a severe replication defect of, as
et, unknown cause. The defect has nothing to do with
he encroachment of the deletion on the primer binding
ite nor is it solely due to a packaging defect. The
berrant protein expression detectable in antibiotic-re-
istant cells stably transfected with MPSA and in tran-
FIG. 5. Slot blot of virion preparations normalised for RT from stably
transfected SV2 cell lines. Lane 1, SW2/MPSC1; lane 2, SV2/MPSB7;
lane 3, SV2/wt pool (pSHRM15 nonclonal cell line); lane 4, SV2/wt 1A
(pSHRM15 clonal cell line); lane 5, SV2/wt pool; and lane 6, original SV2
cell line. Plus and minus signs refer to pretreatment with sodium
hydroxide to ensure detection of RNA specifically.
T AL.FIG. 6. Diagram of the two MPMV-based vectors. Shaded boxes
indicate viral LTRs. C is the packaging signal in the leader region.
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affected RNA transport or caused aberrant translation.
The detection of Pr68, which is indicative of an internal
initiation at a methionine in Matrix, suggests that an
important cis-acting function has been impaired which
ermits usage of the normal AUG. MPMV is known to
ave a cis-acting sequence at the 39 end of the genome
(the CTE) (Bray et al., 1994) and it is conceivable that
further important cis-acting functions depend on se-
quences at the 59 end. The deletion covers the con-
erved stem loop which is implicated in recognition of
he RNA for viral encapsidation but in addition, in the
reviously published secondary structure model (Harri-
on et al., 1995), several other stable structures of un-
known function are seen 59 of this.
The MPSB deletion does not affect RNA stability sig-
nificantly. The RNase protection assay confirmed the
presence of adequate cellular RNA and both the tran-
sient and stable transfections confirmed that translation
of MPSB was satisfactory evidenced by viral protein
production. The reduced level of viral protein is, as yet,
unexplained but seems posttranscriptional. We have
published that the 59 untranslated region of lentiviruses
is capable of affecting translation (Miele et al., 1996) and
in other retroviruses internal ribosome entry sites have
been identified in the leader (Berlioz and Darlix, 1995).
Notwithstanding this, the MPSB deletion does not com-
pletely abolish RNA or protein production and viral par-
ticles are produced which are easily detectable by im-
munoprecipitation and on reverse transcriptase analysis.
Strikingly, the MPSB deletion leads to a marked reduc-
tion in RNA encapsidation of these virions, as shown by
RNase protection in transient transfection and by slot-
blot analysis in the stably expressing cell lines. The
defect was more profound in the latter (Fig. 5). This
probably reflects the increased packaging of packaging-
defective RNA when overexpressed, as occurs in the
COS cell transfection RNase protection assay (personal
observations). The site of the deletion correlates with the
aforementioned stable conserved secondary structure in
the leader sequence and supports our contention that
this GC-rich stem with its conserved GAYC motif may be
critically involved in RNA–protein interactions involved in
packaging. The MPSC deletion has little effect on viral
RNA and protein production. Both are lower than the
wild-type virus in transient and in stable transfection
experiments. The proportion of RNA detected in virions is
similar to that in the wild-type virus, suggesting that the
region between splice donor and gag ATG does not
contribute to RNA packaging of this virus. In some vi-
ruses, including MuLV and HIV-1, cis-acting packaging
sequences are found downstream of the major splice
donor, which is unique to the unspliced RNA. This has
led to the suggestion that this is a favoured site for
MASON-PFIZER MONKEY Vcis-acting packaging signals (Linial and Miller, 1990).
The previous published work on MPMV packaging (Vileet al., 1992) speculated that a packaging signal would
most likely be found in this site downstream of the major
splice donor. However, in our analysis, MPMV appears to
fall into the category of viruses which include RSV (Linial
and Miller, 1990; Katz et al., 1986) and HIV-2 (McCann
and Lever, 1997), in which packaging signals are present
upstream of the major splice donor. The fact that closely
related viruses, such as HIV-1 and HIV-2, have packaging
signals in such different sites indicates that their pres-
ence in a region unique to the unspliced message is not
essential or predictable. In some viruses, the presence
of a packaging signal on the unspliced RNA produces
encapsidation and specificity problems which the virus
overcomes by cotranslational packaging (Kaye and
Lever, 1999).
We have demonstrated that it is possible to generate
pooled and clonal cell lines expressing MPMV proteins,
including those which express a packaging-defective
virus, and that these constitute first-generation packag-
ing cell lines. We have also demonstrated that a first-
generation producer cell line can be generated which is
capable of effecting gene transfer, albeit inefficiently, to
target cells. Clearly, optimisation of this system would be
needed before it was of use in gene transfer studies in
vitro or in vivo. The pantropism of the MPMV envelope,
however, is an added incentive to development of this
nonpathogenic virus as a gene vector. Such studies are
under way in our laboratory.
MATERIALS AND METHODS
DNA plasmids and mutagenesis
The proviral clone used for these experiments was the
pSHRM15 replication-competent clone of MPMV (Rhee
et al., 1990) which contains a hygromycin resistance
gene in its flanking sequence. This allowed production of
stable cell lines containing the intact provirus or the
deletion mutants. Deletion mutagenesis was carried out
using the Kunkel technique (Kunkel et al., 1987) in a
subclone of the pSHRM15 containing the NarI to SacI
fragment. The mutants were confirmed by restriction
analysis and by nucleotide sequencing before being
recloned back into the pSHRM15 proviral clone, where
they were again verified (Fig. 1).
MPMV-based vectors p16.2 and 16.5 were constructed
as follows (Fig. 6): the MPMV proviral clone was deleted
between two DraII sites (1841 to 7436), removing the
complete pol and pro ORFs together with the majority of
gag and env genes, leaving intact the 59 and 39 UTRs, the
packaging signal, the cis-acting sequences required for
reverse transcription, and the CTE. This was inserted
into a PTZ18R backbone and between the BamHI and
HindIII sites was inserted either an SV40 promoter driv-
859 PACKAGING SEQUENCEing a puromycin gene derived from the plasmid pBabe-
Puro in sense orientation with respect to the vector or a
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the vector.
Cell lines
COS1 and COS7 cells were purchased from the Euro-
pean Cell Culture Collection. The SV2 cell line was a gift
of Dr. Francois Guesdon, 293T cells were a gift of Dr.
Paula Cannon, and SW480 cells were kindly provided by
the MRC AIDS Reagent Project. The CMMT cell line is a
known high MPMV producer and is a coculture of rhesus
monkey mammary tumour cells with primary or early
passage monkey embryo cells (Bradac and Hunter,
1984). All these cell lines were maintained and subcul-
tured in DMEM supplemented with 10% FCS, 2 mM
L-glutamine, and 1% penicillin–streptomycin (all from
ibco-BRL), at 37°C in 5% CO2.
Transfections
Transient transfections were performed by the modi-
fied calcium phosphate technique (Chen and Okayama,
1987). After overnight incubation in transfection medium
in a 3% CO2 incubator, the medium was changed for
standard DMEM and the cells were transferred to a 5%
CO2 incubator at 37°C prior to analysis of virions and
ells. Plasmid DNA (transfected usually at 10 mg per
10-cm petri dish) was purified on cesium chloride gradi-
ents or on Qiagen columns.
Permanent transfectants were obtained following
electroporation of FspI-linearised constructs into SV2
and SW480 cells at 1000 V, 25 mV, using a Gene Pulser
II (Bio–Rad) in serum-free DMEM. Following electropo-
ration, cells were maintained for 10 min on ice and then
transferred to standard tissue culture dishes and grown
at 37°C, 5% CO2, with one medium change at 24 h
followed by initiation of antibiotic selection 48 h post-
transfection. Hygromycin was obtained from Sigma and
used at a concentration of 280 mg/ml for SV2 cells and
50 mg/ml for SW480 cells. Selection media were
hanged at least twice weekly. Where indicated individ-
al clones were removed from the transfected cell pop-
lation and grown separately, initially in six-well plates
efore being expanded for analysis.
everse transcriptase assay
Virion containing supernatant (3 ml) was briefly spun
t low speed at 4°C for 10 min to clear cellular debris.
he resulting supernatant was then spun at 80,000 rpm
n a TLA 100.3 rotor (Beckman) at 4°C for 15 min, and the
upernatant from that spin discarded. The viral pellet
as dissolved in 30 ml of lysis buffer (50 mM Tris, pH 7.8,
100 mM KCI, 0.05% Triton X-100, 2 mM dithiothreitol) by
vortexing for 30 s and left on ice for 15 min. The RT assay
was carried out on 10-ml aliquots, in duplicate, with the
86 GUESDQuant-RT kit (Amersham, UK) as specified by the manu-
facturer. The reaction was stopped after 60 min of incu-bation at 37°C, and the RT values were determined
immediately on a Beta-counter (Packard Beta Rack).
Virion and cellular RNA preparation
Virion RNA preparation initially followed the same pro-
tocol as that described for RT. The high-speed pellet was
resuspended in guanidinium thiocyanate. RNAs were
prepared using the method described by Chomsczinski
and Sacchi (1987). The RNAs were used after two etha-
nol precipitation steps and resuspension in RNase-free
H2O. For preparation of intracellular RNAs, the cells were
craped off the tissue culture dish after two washes with
old PBS, resuspended in the guanidinium thiocyanate
uffer, and then treated as described above. The total
ellular RNA concentrations were determined by OD
eadout at 260 nm.
NA slot blots
Total cellular RNAs (5 mg per well) and equivalent RT
alues of virion RNAs for all samples were blotted onto
eta-Probe membrane (Bio–Rad) in final volumes of 500
ml, as recommended by the manufacturer, using a slot-
blot apparatus. All wells were washed once with RNase-
free H2O, and the membrane was soaked in 23 SSC for
few seconds and then dried at room temperature
efore baking for 2 h at 80°C. The membranes were
rehybridised in 10 ml of prehybridisation buffer (0.25 M
a2HPO4, pH 7.2, 7% SDS) for an hour at 65°C in rollers
in a Techne Hybridisation Oven. The probes used were
the SphI–NarI segment of pSHRM15 (positions 171 to
350, in the 59 LTR), and the GAPDH probe was the
1100-bp human GAPDH cDNA insert. The randomly la-
belled probes (Random Primed DNA Labelling kit, Boeh-
ringer Mannheim Biochemica) were added to the prehy-
bridisation media after denaturation at 100°C for 10 min
followed by rapid cooling, and the hybridisation was left
at 65°C for 16 h. After two rinses with 23 SSC at room
temperature, the membranes were washed twice with
23 SSC, 0.1% SDS, for 30 min, first at room temperature
and then at 65°C, and twice with 0.13 SSC, 0.1% SDS, for
30 min, first at room temperature and then at 65°C. The
membranes were exposed overnight to Kodak XAR film
with intensifying screens, at 280°C. RNA was estimated
using laser densitometry.
RNase protection assay
Total cellular RNAs and extracellular virion RNAs were
analysed with the RPA II kit (Ambion). The plasmid yield-
ing the antisense RNA probe to the region under study
(plasmid R611) was constructed as follows: the 605-bp
fragment from pSHRM15 (from SphI at position 171 to an
HpaI site at position 776) was cloned into the pTZ18U
vector (USB) cut by SmaI and SphI. After linearisation by
T AL.HindIII digestion, the riboprobe was synthesised from
the T7 promoter as a 633-nucleotide labelled RNA span-
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gag ORF, using the MAXIscript in vitro transcription kit
from Ambion. The control riboprobe was a segment of
human b-actin antisense message (pTR1-b-actin-Human
plasmid, from Ambion), which yields a 245-bp protected
fragment when analysed by RNase protection assay. The
size markers were the RNA Century Markers (Ambion),
ranging from 100 to 500 bp and synthesised in vitro
following the manufacturer’s protocol.
RNA levels were calculated by scanning densitometry
and the packaging level was calculated by comparing
cellular:virion spiced:unspliced RNA as previously de-
scribed (Richardson and Lever, 1995). The packaging
efficiency of the mutants was measured relative to that of
wild-type virus.
Pulse–chase labelling
Subconfluent 60-mm-diameter tissue culture dishes
were labelled as follows: The cells were washed twice
with PBS and starved in 5 ml of prewarmed Met2 Cys2
DMEM for 1 h at 37°C in 5% CO2. The medium was then
discarded and replaced by 500 ml of DMEM Met2 Cys2
(ICN-Flow) containing 150 mCi of 35S-Protein Labelling
ix (NEN). The cells were incubated for 15 min and
ither lysed immediately (“pulse”) or washed with com-
lete medium and returned to the 5% CO2 incubator for
varying lengths of time (“chase”) in complete medium.
Cell lysis was done after a wash with cold TBS, pH 7.5,
and incubation of the cell pellet in lysis buffer (1% Triton
X-100, 25 mM Tris–HCl, pH 8.0, 50 mM NaCl, 1% sodium
deoxycholate) for 10 min on ice. After pelleting the nuclei
by centrifugation for 5 min in a microfuge, SDS was
added to a final concentration of 0.1%. All cytosols were
precleared by incubation with inactivated Staphylococ-
cus aureus as described in Bradac and Hunter (1984)
prior to immunoprecipitation, for 30 min at 37°C.
Labelled virions were extracted from the pelleted su-
pernatants collected at the end of the different “chases,”
as described for the RT assay. The high-speed pellet was
resuspended in ice cold lysis buffer and treated thereaf-
ter as the cell pellets had been.
Immunoprecipitation
Half of each volume of the supernatants from the
preclearing step was incubated with 1 ml of goat anti-
MPMV antibody (Bradac and Hunter, 1984) per 500-ml
ample and left at 4°C overnight. The immune com-
lexes were precipitated by addition of inactivated S.
aureus for 30 min at 37°C and pelleting. The resulting
pellet was washed three times with 20 mM Tris–HCl, pH
7.5, and resuspended in 20 ml Laemmli buffer 23, soni-
cated for 30 s, and boiled for 2 min prior to being loaded
onto an 11% PAGE minigel (Bio–Rad Protean II appara-
MASON-PFIZER MONKEY Vtus). The electrophoresis was performed at 150 V and the
gels were stained, destained, amplified (Amplify, Amer- Ksham), and exposed to Fuji films at 280°C. Prestained
M r standards were purchased from Gibco-BRL.
ector transfer
An SV2 cell line stably transfected with the MPSB
eletion of MPMV was used as a first-generation pack-
ging cell line. Stable producer cell lines were con-
tructed by calcium phosphate-mediated transfection of
he p16.2 and p16.5 vectors into aliquots of the SV2
PSB cells. The relevant selection was applied and
esistant colonies were picked and grown under selec-
ion. Southern blotting of producer cells from this work
emonstrated rearrangement of the p16.2 vector but an
ntact p16.5 (not shown). Supernatants from this latter
ell line were harvested and 0.45-mm filtered and virions
recipitated using an equal volume of 30% PEG/0.4 ml
aCl at 4°C overnight followed by centrifugation for 45
in to pellet the virus. The pellets were resuspended in
MEM and used to infect either HeLa B or SV2 target
ells which were subsequently selected with puromycin.
esistant colonies were counted at 2 weeks and a titre
as back calculated from the volume of supernatant
riginally used for vector production.
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